BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Positive Clinical Results: BiomX reported successful Phase 2 results for BX211, showing over 40% wound size reduction in diabetic foot osteomyelitis patients compared to placebo, and is planning a potential registrational study. Additionally, new data for BX004 indicated a significant bacterial reduction with no resistance observed, supporting the efficacy of their phage therapy platform.

Financial Overview and Future Plans: The company announced a cash balance of $15.2 million as of June 30, 2025, sufficient to fund operations into Q1 2026. They are also progressing with the Phase 2b trial of BX004 in cystic fibrosis patients and expect to report topline results in early 2026, while awaiting FDA feedback on their real-world evidence strategy later this year.